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A latent reactive handle for functionalising
heparin-like and LMWH deca- and
dodecasaccharides†
Gavin J. Miller,a Karl. R. Broberg,a Claire Rudd,a Madeleine R. Helliwell,b
Gordon C. Jaysonc and John M. Gardiner*a
D-Glucosamine derivatives bearing latent O4 functionality provide modiﬁed H/HS-type disaccharide
donors for a ﬁnal stage capping approach enabling introduction of conjugation-suitable, non-reducing
terminal functionality to biologically important glycosaminoglycan oligosaccharides. Application to the
synthesis of the ﬁrst O4-terminus modiﬁed synthetic LMWH decasaccharide and an HS-like dodeca-
saccharide is reported.
Introduction
The glycosylaminoglycan (GAG) family of carbohydrates consti-
tute the most diverse group of biological carbohydrates. They
are pervasive on cell surfaces and within the intra-cellular
matrix, playing key roles in mediating regulatory functions
relevant to numerous biomedical areas, such as cancer,
inflammation, Alzheimer’s disease, viral infectivity, and stem
cell diﬀerentiation.1 Heparin and heparan sulphate (H/HS) are
key members of this GAG family of sugars. The complex
heterogeneity of the natural oligosaccharides requires synth-
eses of structurally-defined HS sequences to be able to evaluate
the roles of HS substructures, which underpins the potential
for ultimate therapeutic applications of synthetic fragments.
Such synthetic endeavours have seen a number of important
advances in recent years, targeting both anti-coagulant
LMWH-replacements,2 but wide interest is directed at the
diversity of bio-regulatory roles diﬀerent synthetic heparin-like
oligosaccharides could target.3
As part of our program to provide scalable syntheses of
structurally-defined H/HS oligosaccharides, encompassing the
first reported [GlcN-IdoA]n 12-mer LMWH
4 and gram-scale
syntheses of heparin-like 12-mers,5 we have also been develop-
ing synthetic HS mimetics bearing a site-specifically located
functional handle, to provide new GAG tools for chemical
biology and biophysical applications of homogenous oligosac-
charide conjugates.
Accessibility to new synthetic oligosaccharides bearing
functional end groups is highly relevant to the viability of
applications to microarray analysis, fluorescent labelling and
other biomolecule or nanoparticle conjugations, essential for
interrogating biological structure/function eﬀects. Chemical
modifications generating new carbohydrate tools are impor-
tant, not only for the glycosaminoglycan field,6 but for wider
potential applicability within the chemical glycobiology
community.7
End-modification methods for native linear poly- and oligo-
saccharides, including GAGs, traditionally employ reductive
amination chemistry at the expense of opening the reducing
terminal sugar.8 Conjugation-amenable modifications which
do not require a free reducing terminus are important. Modifi-
cations via the glycosidic terminus have become the default
strategy for glycoside conjugation capabilities for GAGs and
other oligosaccharides. Most of these approaches introduce
glycosidic extensions bearing reactive amine, thiol, alcohol,
azide or alkyne functions for further modifications. In the
GAG and wider saccharide arena, these have seen valuable
applications to arrays and other immobilizations,9 and recent
end modifications to assist purification and thereby accelerate
synthesis, such as through use of ionic liquid9e or fluorous9f
tags. Invariably, the reducing terminus is employed for
C1 modification via O-, but also C-, N- or S-glycosides.
Though of high biological and biomedical importance, the
challenges presented by chemical synthesis of longer synthetic
heparins has limited approaches to end-modifications. A redu-
cing terminal labelling approach via disaccharide iteration
(Fig. 1A) requires that the conjugation site or precursor is
introduced early and is followed by all the sequence iterations.
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Use of reactive aldehyde end tags can be envisaged as an
alternative to use of a free reducing terminus (aldehyde) by
installing the aldehyde on a linker, and though little exploited,
has also seen use for amination-based facile dimerization of
disaccharides.10 We recently reported introduction of a redu-
cing end latent aldehyde tag (LAT) into a synthetic HS-dodeca-
saccharide and exploited this for 3H-radiolabelling, enabling
the first example of determination of in vivo tissue distribution
and metabolism of a pure, biologically-active heparin-like
oligosaccharide (c.f. Fig. 1A).11 This reducing terminal modifi-
cation approach was considerably facilitated by the high
eﬃciency and fidelity of a new 4-mer based iteration 12-mer
synthesis to two 2-step cycles, however, in this case still, the
latent conjugation site (at the reducing terminus) is included
from the beginning of the iterations.
Non-reducing terminal conjugation units would obviate the
limitation of early-stage introduction of the commonly-
employed O1-glycosidic based conjugate-ready modifications
for iterative oligosaccharide synthesis and would be antici-
pated to deliver increasing benefits for longer heparanoids. In
such approaches, all but the final iteration step would precede
introduction of the latent conjugation site (Fig. 1B). Following
our 12-mer HS end-labelling work, we therefore sought to
investigate the utility of attaching such a LAT, or similar
derivative, to the non-reducing terminus of heparanoid oligo-
saccharides. This has not been evaluated or exploited for the
functional modification of longer, bio-relevant heparin-types
or other GAGs. This would be valuable both for H/HS targets,
but we envision such end modification would be portable to
application in other important GAGs, of diﬀerent constituent
sequences. Given the known biological roles of O6 and O3
D-GlcN functionality in H/HS systems, this would most ideally
be located at the O4 terminal position (Fig. 1B). A non-redu-
cing terminal strategy could seek to modify the terminus post-
oligomerization, via coupling to a native terminal hydroxyl
unit which could be methodologically challenging. Instead,
providing new generic end-modified non-reducing ‘capper’
units (e.g. disaccharides) would introduce a terminal, non-
reducing end building block (Fig. 1B) bearing the latent conju-
gation site in the final iterative glycosylation step during oligo-
saccharide assembly. This convergent strategy would be
attractive as it would enable late-stage diversification at the ter-
minus of diﬀerent acceptor saccharides and accelerate accessi-
bility to HS-sequences of diﬀerent constituents or containing
mixed sulfation patterns, in a parallel manner.
Introducing this to our [GlcN-IdoA]n-based HS oligosacchar-
ide synthetic strategy requires attaching a conjugation-suitable
tag containing a terminal reactive group (or latent reactive
group) at the D-GlcN-O4-position. Ideally, this would be incor-
porated into a GlcN-IdoA disaccharide donor unit, two variants
of which we have shown are eﬀective iduronate donors, whose
coupling rections are routinely high yielding and highly anom-
erically selective, on even the longest synthetic heparin-like
acceptors.4,5,12
Such O4 modification could be approached by attaching
the protected handle either directly at disaccharide level or
onto the monoglucoside, which could then be coupled with an
L-idoA acceptor, providing reagent disaccharides.
Prior examples of D-GlcN derivative O4 alkylations and
related modifications include a 4-position formyl moiety (via
reduction of a 4-cyano species),13 ethanolamine based linkers
for introducing BODIPY fluorophores,14 diethylene glycol
derivatives for azide-based linkers,15 thiol terminated alkyl
spacer units (via thiol addition to O-allyl)16 and carboxylate ter-
minated linkers.17
Results and discussion
We report here approaches to introduce diﬀerent oxidation
level end groups, namely a carboxylate or an aldehyde surro-
gate, directly onto a D-GlcN-O4 derivative with an anomeric
donor group in place (thiophenyl). Both these functional
groups would facilitate further complementary conjugation
Fig. 1 A: Reducing terminal vs. B: ﬁnal stage capping approaches to
introduce functional end groups into HS-like oligosaccharides, R = Me,
R’ = Bz or Bn.
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chemistries. Our strategy was to introduce the O4 unit into
suitable D-GlcN monosaccharide derivatives and to then
couple to an iduronate acceptor as a direct route to end-modi-
fied ‘capper’ disaccharides. We also sought to evaluate such
O4 modification via a pre-prepared disaccharide.
Alkylation of D-GlcN-O-4 derivatives with carboxylate-bearing
tethers
A first strategy considered introducing an O4 tag bearing a car-
boxylate, envisaging ultimate late-stage applications with suit-
ably reactive labelling nucleophiles. Whilst a suitable ester
diﬀerentiation for the iduronate might prove necessary, we
reasoned that diﬀerential reactivity of a spacer-linked carboxy-
late over the L-IdoA 2-carboxylate could be evaluated or
eﬀected by use of a diﬀerentially labile terminal ester. Ethyl-
bromoacetate was first employed as a model electrophile for
D-GlcN O4-alkylation. Reaction of ethylbromoacetate with the
O4 alkoxide salt of glucosamine derivative 118 (Scheme 1)
aﬀorded the target ester 2, but in relatively poor yield, owing to
degradation of the starting material. However, with novel 2 in
hand, saponification to the carboxylate derivative 3 proceeded
in 81% yield. A more eﬃcient one step route from 1 to 3 was
subsequently eﬀected using alkylation direct with iodoacetic
acid in DMF, aﬀording the acid 3 in significantly better overall
yield (71%). If advancing this type of linker, a modified L-IdoA
ester would thus be the candidate for any subsequent disac-
charide formation.
Carboxylate 3 was utilised to evaluate model attachment of
two fluorescent units, 419 and 5,20 which contained diﬀering
length C2 or C6, diaminoalkyl linker units, oﬀering a divergent
access to fluorescently tagged D-GlcN building blocks 6 and 7
(Scheme 2). Coupling of 4 or 5 with 3 using standard amide
bond forming reagents aﬀorded the fluoro-tagged D-GlcN
derivatives 6 and 7, respectively. This provides evidence for the
potential viability of similar derivatization of D-GlcN
embedded in longer chains. This approach also envisaged that
such novel O4-carboxylate-bearing D-GlcN species could be pre-
cursors to extensions with other latent tag units via amide
linkages.
We sought to evaluate whether this approach could be
applied to the construction of an end-labelled HS-like di-
saccharide. This would establish the potential to use a pre-
labelled HS disaccharide capper unit. Thus, the coupling of
NBD-monosaccharide derivative 6 with L-iduronate acceptor 8
was attempted using NIS (1.5 equiv.) and AgOTf (0.1 equiv.).
However, whilst disaccharide coupling occurred to form 9,
this was in modest yield, with significant amounts of acceptor
recovered. Further inspection of the MS data showed a surpris-
ing concomitant iodination of the electron-deficient NBD ring
(Scheme 3).
Attempts to couple pyrene-labelled glucoazide donor 7 with
L-iduronate acceptor 8 returned hydrolysed donor and
unreacted acceptor from the reaction mixture, under the same
Scheme 1 D-GlcN O4 modiﬁcations with activated carboxylate/ester
electrophiles.
Scheme 2 Fluorescently tagged glucosamine derivatives 6 and 7.
Scheme 3 Fluorescently tagged disaccharide synthesis.
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conditions employed for 9. This suggested a poor capability of
7 as a glycosyl donor and, coupled with the unexpected glyco-
sylation reactivity of 6, suggested that a carboxylate-based
approach would require further development to be viable.
Our alternative approach was via a D-GlcN O4-aldehyde-level
bearing unit, which would remain latent throughout synthetic
mono-, di- and oligosaccharide construction. This would paral-
lel our O1-linked LAT approach and enable a final stage alde-
hyde unmasking on the complete sulphated heparin-type
oligosaccharides.21 This would also obviate the need to carry a
fluorescently labelled system throughout the remainder of the
synthetic transformations to a complex HS target, which might
have been necessary, if selective O4-ethanoate coupling were to
prove problematic over internal L-IdoA carboxylate reactivity.
Alkylation of D-GlcN derivatives with latent aldehyde O-4
tethers
Alkylation attempts of 1 with aldehyde- or protected aldehyde-
containing electrophiles such as 3-bromo-1,1-dimethoxy-
propane, 4-bromomethylbenzaldehyde, 3-bromomethyl-
benzaldehyde and 2-(4-(bromomethyl)phenyl)-1,3-dioxolane
were unsuccessful, mostly leading to no alkylation product
and frequently to degradation of the starting D-GlcN derivative.
We thus evaluated use of allylbromide to alkylate the O4 posi-
tion of 1 with a view to using the derived alkene as an alterna-
tive precursor to a 1,2-diol aldehyde surrogate. Allylation of 1
was eﬀected in 97% yield (Scheme 4) and subsequent OsO4-
mediated dihydroxylation of 10 furnished diol 11 in 98% yield.
Double benzylation of 11 was completed in high yield to
aﬀord 12 with the required masked 1,2-diol unit installed at
the O4-position. 1H NMR indicated that the penultimate di-
hydroxylation reaction to aﬀord diol 11 yielded a mixture of
diastereomeric diols (2 : 1, R/S). As the diol chiral centre is lost
in the anticipated release of the aldehyde at the end of any lab-
elling route, we envisaged this could be pursued using disater-
eomerically-mixed diol, once late stage analytical methods
were in place. The crystal structure of 11 showed a 3 : 1
diastereomeric ratio (R : S configuration of the diol side chain)
in the crystal, with a mixed packing of the two diastereomers
(Fig. 2). In addition, the major (side chain R) diastereoisomer
adopted two diﬀerent conformations varying about several
torsion angles in the O4 diol-bearing unit, whilst there are no
significant diﬀerences in any aspects of the sugar ring or
derivatives (such as the SPh or azide) on the ring, for either
conformer or between diastereomers.
The monosaccharide building block 12 was suitable for
glycosylation with an iduronate acceptor 19 and provided the
required, iteration-ready, HS-like disaccharide building block
in three steps and 19% overall yield in a manner directly ana-
logous to that for diastereomerically pure 20 and 21 (vide
infra).‡ Although it is not critical that the OsO4 mediated dihy-
droxylation of 10 did not proceed with complete diastereo-
selectivity (as stereochemistry lost on late-stage aldehyde
release), we explored an alternative access to a diastereomeri-
cally-pure form of 12 to circumvent any analytical challenges
of late stage oligosaccharide synthesis and characterisation
using stereoisomeric mixtures, and to aﬀord high purity final
targets for analysis and structural proof.
Having successfully employed a dibenzyl glycidol unit as an
O1-LAT (via glycosylation)11 we sought to evaluate a similar
unit introduced via O4 alkylation. This presented the same
potential complications we had encountered in O4-alkylation
with a number of unactivated electrophiles (vide supra).
(S)-2,3-Dibenzyloxy propanol was readily converted to its
tosylate derivative 1322 and subsequent alkylation of 1 with 13
did proceed, but only in low yield, as the reaction required
heating, and as we had seen with other O4 alkylations,
resulted in competing starting material degradation
(Scheme 5). To circumvent this, employing the corresponding
triflate electrophile 1423 enabled eﬃcient alkylation of O4 for
two D-GlcN derivatives β-1 and 16 (diﬀerentially protected at
O6) in good to excellent yields. The slightly lower yield for the
formation of 18 was attributed to a competing transesterifica-
Scheme 4 Synthesis of D-GlcN O4-glycidols 12 via allylation–
oxidation.
Fig. 2 X-Ray crystal structure for diastereoisomers of diol 11 (major:
R conﬁguration in diol side chain; minor: S-conﬁguration in side chain).
‡Data not shown.
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tion reaction, evidenced by formation of a species with very
similar Rf to 18 as the reaction progressed. The reaction yield
was improved by drop-wise addition of the electrophile at 0 °C.
Commercially available (S)-2,3-dibenzyloxypropanol is
expensive (£100 per g). We thus developed a convenient 5-step
route from D-mannitol (3 orders of magnitude cheaper than
(S)-2,3-dibenzyloxypropanol), which readily delivered multi-
gram quantities of the required alcohol (25% overall yield,
5 steps from D-mannitol, see ESI†).24 This enabled us to access
the novel O4-LAT derivatized thioglyosides 17 and 18 in gram
quantities and diastereomerically pure form. The inclusion of
the diﬀerential O6 protection is important as this allows paral-
lel access to backbone O6-sulfation pattern variations in any
final HS-oligosaccharide targets.
With these materials in hand we then investigated their utility
for synthesis of end-tagged HS-related di- and oligosaccharides.
Synthesis of heparin-like di- and oligosaccharides bearing a
functional non-reducing end tether
Thioglycoside derivatives 17 and 18 were readily converted to
their respective trichloroacetimidate donors in high yield, fol-
lowing NBS-mediated hydrolysis. Subsequent glycosylations
with iduronate acceptor 19 aﬀorded the expected high selecti-
vity for the desired α-1,4 linkage, aﬀording 20 (for H1′ δ:
4.61 ppm, d, J = 3.6 Hz) and 21 (for H1′ δ: 4.72 ppm, d, J = 3.6
Hz). Synthesis of both of these novel O4-modified disacchar-
ides could be readily carried out on multi-hundred mg scale
with the synthesis of 20 additionally scaled to gram level
(Scheme 6). In each case iduronate accepter 19 was recovered
(around 30% for 21 and 35% for 20) following chromato-
graphy, suggesting a lower reactivity of the donor thioglycoside
in these systems, compared to direct analogues lacking the
modified O4-unit.
We attempted the direct alkylation of an analogue of di-
saccharide 21, containing a free 4-OH at the non-reducing end
terminus, with triflate 14, but no product was observed. With
recovery of iduronate acceptor in disaccharide synthesis and
the poor alkylation of a disaccharide, this overall validated the
more convergent strategy of including an O4 modification at
the disaccharide level, and not by attempting its introduction
into longer oligosaccharide sequences.
With disaccharide building blocks 20 and 21 available we
sought to demonstrate their application to synthesis of longer
O4-tagged HS and LMWH-related oligosaccharides. To illus-
trate the capacity to access diﬀerent lengths and backbone sul-
fation types, the strategy was as outlined in Scheme 7, capping
Scheme 5 Diastereomerically pure O-glycidol-bearing D-GlcN deriva-
tives 15–18.
Scheme 6 Synthesis of O4-end modiﬁed disaccharide donors.
Scheme 7 Strategy for end-capping to heparin and LMWHs bearing
non-reducing terminal O4 diol tag, R = Bn or Bz.
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acceptor octa- and decasaccharides with our diﬀerentially O6-
derivatized O4-LAT-bearing “capper” disaccharides, which,
after deprotection and sulfations, thereby aimed to provide
O4-terminal diol tag bearing deca- and dodecasaccharides.
This would establish this as a route to the longest currently
available end-modified synthetic heparin- or LMWH-like oligo-
saccharides. It would also illustrate applicability to both
diﬀerent O6 sulfation systems, including LMWH. If successful,
then release of an aldehyde terminus could be eﬀected ana-
logously to our O1-LAT release using NaIO4.
Scheme 8 Synthesis of LMWH deca- and HS-like dodecasaccharides with non-reducing end latent aldehyde tethers and conversion to terminal
aldehydes.
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Accordingly, tagged glycosylation-capping of per-GlcN-6-
OBz octasaccharide acceptor 224 with O4-modified disacchar-
ide 21 using NIS and AgOTf at 0 °C, provided the novel end-
tagged decasaccharide 25 in good yield and high anomeric
purity (Scheme 8). Further, the novel dodecasaccharide 24 was
obtained in similarly good yield through tagged glycosylation-
capping of decasaccharide acceptor 235a with O4-modified di-
saccharide 20.
Finally, the fully protected oligosaccharides 24 and 25 were
subjected to standard deprotection and O/N-sulfation steps to
aﬀord the native-type species 26 and 27 bearing non-reducing
end reactive aldehyde groups (Scheme 8).
Analysis of dodecasaccharide 26 by 800 MHz NMR spectro-
scopy indicated formation of a hemiacetal between the free
aldehyde and the 3-position of the terminal glucosamine unit.
This was not unexpected given the potential ease of cyclisation
to form a terminal 6-membered ring system. We are however
confident that the material was homogenous in terms of the
installed sulfation pattern and that the latent motif, whilst pre-
ferring to exist in solution predominantly as an acetal, would
react as an aldehyde in subsequent conjugation/labelling
studies. This was previously demonstrated on our reducing
end analogue HS-like dodecasaccharide, which behaved
smilarly.11
Conclusions
A reliable and scalable synthesis of two non-reducing end
modified GlcN-IdoA disaccharides containing a latent alde-
hyde group enables inclusion into LMWH- and HS-related
deca- and dodecasaccharides. These are the first examples of
such O4-modified heparin-like oligosaccharides. This provides
a new approach to install an O4 tag onto defined HS oligosac-
charide mimetics, which will enable applications in a variety
of labelling and conjugation chemistries. The disaccharide
units are generic tools that should find utility for final iter-
ation stage coupling to diverse heparin-like oligosaccharides.
These reagents also oﬀer scope for exploitation in synthesis of
other D-GlcN-containing oligosaccharides.
Experimental section
Phenyl 2-azido-3,6-di-O-benzyl-4-O-acetoxyethyl-2-deoxy-1-thio-
α-D-glucopyranoside (2)
Glucosamine derivative 118 (2.0 g, 4.2 mmol) was dissolved in
dry THF (20 mL) under nitrogen. NaH (185 mg, 4.6 mmol,
60% in mineral oil) was added and the suspension stirred for
30 min at room temperature. Ethylbromoacetate (510 μL,
4.6 mmol) was added and the suspension heated at 55 °C over-
night (16 h). TLC analysis (EtOAc/hexane, 3 : 1) showed starting
material remained along with product at a slightly higher Rf.
Successive additions of NaH and ethylbromoacetate were
made at 16 h and 24 h. After this time a new spot was seen to
form on the baseline of the TLC plate and the reaction was
stopped (quenching with AcOH). The solution was taken in
EtOAc/H2O (20 mL each), the layers separated and the organics
washed with saturated aqueous NaHCO3, saturated aqueous
NaCl, dried (MgSO4) and solvent removed in vacuo. The crude
material was purified by silica gel flash chromatography,
eluting with EtOAc/hexane, 8 : 1, 5 : 1 to yield 2 (666 mg,
1.1 mmol, 29%) as a clear gum. Rf 0.59 (EtOAc/hexane 1 : 3);
[α]D +120.5 (c = 2.1, DCM);
1H NMR (400 MHz; CDCl3): δ 7.42
(ddt, J = 4.4, 2.8, 1.4 Hz, 2H, ArH), 7.31–7.18 (m, 13H, ArH),
5.52 (d, J = 5.2 Hz, 1H, H1), 4.85 (d, J = 10.5 Hz, 1H, CH2Ar),
4.77 (d, J = 10.5 Hz, 1H, CH2Ar), 4.54 (d, J = 11.9 Hz, 1H,
CH2Ar), 4.37 (d, J = 11.9 Hz, 1H, CH2Ar), 4.36–4.34 (m, 1H, H5),
4.24 (d, J = 15.8 Hz, 1H, CH2C(O)OEt), 4.08–4.03 (m, 3H, CH2C-
(O)OEt, H6B, H4), 3.85–3.74 (m, 3H, OCH2CH3, H2), 3.61 (dd,
J = 11.0, 1.9 Hz, 1H, H6A), 3.55 (dd, J = 9.9, 8.7 Hz, 1H, H3),
1.17 (t, J = 7.1 Hz, 3H, OCH2CH3);
13C NMR (100 MHz; CDCl3):
δ 169.6, 137.9, 137.6, 133.4, 132.2, 129.1, 128.5, 128.4, 128.2,
128.0, 127.8, 127.7, 87.2, 81.7, 79.1, 75.7, 73.4, 71.4, 70.3, 68.3,
64.1, 61.0, 14.3; MS ES [M + Na]+ m/z 586.0; HRMS (TOF+) m/z
calcd for C30H33N3O6SNa [M + Na]
+ 586.1988, found 586.1995.
Phenyl 2-azido-3,6-di-O-benzyl-4-O-acetoxy-2-deoxy-1-thio-
α-D-glucopyranoside (3)
Via saponification from ester 2. To a stirred solution of 2
(259 mg, 0.46 mmol) in THF (3 mL) was added sodium hydrox-
ide solution (0.5 mL, 1 M solution) at 0 °C over 10 minutes.
The mixture was then stirred at room temperature for 6 h
after which time the reaction was shown to be complete by
TLC analysis (EtOAc/Hex, 1 : 1). The reaction mixture was
cooled back to 0 °C, acidified to pH 4 using hydrochloric acid
(1 M), poured onto brine (25 mL) and extracted with ethyl
acetate (3 × 40 mL). The organic layers were combined, washed
with brine (25 mL), dried (MgSO4), filtered and concentrated
in vacuo. The crude product was purified by silica gel flash
chromatography eluting with hexane/ethyl acetate, 4 : 1 to give
acid 3 (199 mg, 0.37 mmol, 81%) as a colourless oil. Rf = 0.21
(EtOAc/Hex, 1 : 2.5); [α]D = +79.2 (c = 1.5, CHCl3);
1H NMR
(400 MHz; CDCl3) δ 7.40–7.39 (m, 2H, ArH), 7.30–7.16 (m, 13H,
ArH), 5.52 (d, J = 5.4 Hz, 1H, H1), 4.88 (d, J = 10.7 Hz, 1H,
CH2Ar), 4.72 (d, J = 10.7 Hz, 1H, CH2Ar), 4.54 (d, J = 11.9 Hz,
1H, CH2Ar), 4.36 (d, J = 11.9 Hz, 1H, CH2Ar), 4.31–4.23 (m, 2H,
H5, CH2CO2H), 4.08 (d, J = 16.7 Hz, 1H, CH2CO2H), 3.84 (dd,
J = 10.2, 5.4 Hz, 1H, H2), 3.75–3.70 (m, 2H, H4, H6B), 3.57–3.51
(m, 2H, H3, H6A);
13C NMR (100 MHz, CDCl3) δ 137.2, 136.8,
132.9, 131.9, 129.0, 128.9, 128.5, 128.4, 128.2, 128.1, 127.7,
127.6, 127.5, 86.9, 80.7, 78.8, 73.3, 70.9, 69.9, 68.1, 63.9; MS
NSI [M − H]− m/z 534.2; HRMS (FTMS NSI−) m/z calcd for
C28H28N3O6S1 [M − H]− 534.1704, found 534.1710.
Via reaction of 1 with iodoacetic acid. To a solution of
1 (1.0 g, 2.10 mmol) in anhydrous DMF (10 mL) was added
NaH (350 mg, 14.6 mmol, 60% in mineral oil) and KI (600 mg,
3.62 mmol) and the suspension stirred under nitrogen at 0 °C
for 30 minutes. After this time iodoacetic acid (1.1 mL,
2.42 mmol) was added drop-wise and the reaction solution
stirred at ambient temperature for a further 15 h. TLC analysis
(EtOAc/Hex, 1 : 1) then indicated the reaction was incomplete
Paper Organic & Biomolecular Chemistry
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and further NaH (70 mg, 2.92 mmol) and iodoacetic acid
(0.2 mL, 0.48 mmol) were added and stirring continued
for 6 h at 40 °C. Upon completion (as adjudged by TLC) the
reaction solution was cooled to ambient temperature,
diluted with distilled H2O (15 mL) and extracted with EtOAc
(4 × 10 mL). The combined organics were then washed with
H2O (5 × 10 mL), dried (MgSO4) and solvent removed in vacuo.
The crude acid 3 was purified by silica gel flash chromato-
graphy eluting with hexane : EtOAc, 3 : 1, 1 : 1 to aﬀord
3 (800 mg, 1.50 mmol, 71%) as a pale orange oil. Analytical
data matched those above.
NBD-D-GlcN derivative (6). NBD-amine salt 419 (29 mg,
0.11 mmol), acid 3 (69 mg, 0.13 mmol), TBTU (41 mg,
0.13 mmol) and DIPEA (34 μL, 0.194 mmol) were dissolved in
anhydrous DMF (4 mL) under nitrogen and stirred for
46 hours until the reaction was shown to have reached com-
pletion by TLC analysis (EtOAc/Hex, 1 : 2). The reaction was
diluted with diethyl ether and washed with water three times.
The organic phase was dried (MgSO4) and concentrated
in vacuo. The crude material was purified by silica gel flash
chromatography eluting with hexane/ethyl acetate, 3 : 1 to yield
6 as a yellow oil (40 mg, 0.05 mmol, 42%) Rf = 0.71 (hexane/
EtOAc 3 : 1); [α]D (c = 1.5, DCM) +24.9;
1H NMR (400 MHz;
CDCl3) δ 8.31 (d, J = 8.6 Hz, 1H, NBD-ArH), 7.79–7.76 (brs, 1H,
NH), 7.60–7.58 (brs, 1H, NH), 7.42–7.38 (m, 2H, ArH),
7.32–7.18 (m, 13H, ArH), 5.87 (d, J = 8.6 Hz, 1H, NBD-ArH),
5.54 (d, J = 5.5 Hz, 1H, H1), 5.01 (d, J = 10.6 Hz, 1H, CH2Ar),
4.61 (d, J = 10.6 Hz, 1H, CH2Ar), 4.48 (d, J = 11.7 Hz, 1H,
CH2Ar), 4.40 (d, J = 11.7 Hz, 1H, CH2Ar), 4.23–4.19 (m, 2H,
CH2C(O)NH, H6B), 4.12 (d, J = 16.3 Hz, 1H, CH2C(O)NH), 3.86
(dd, J = 10.2, 5.5 Hz, 1H, H2), 3.68–3.64 (m, 2H, H3, H5),
3.56–3.51 (m, 2H, H4, H6A), 3.10–3.07 (m, 3H, NHCH2CH2NH),
2.91–2.87 (m, 1H, HCH2CH2NH);
13C NMR (100 MHz, CDCl3)
δ 172.4, 144.2, 143.9, 137.1, 136.8, 136.6, 132.9, 132.1, 129.2,
129.1, 128.9, 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 87.2, 81.1,
78.3, 76.1, 73.7, 71.4, 70.7, 68.4, 64.4, 37.5; MS ES [M + Na]+
m/z 763.0; HRMS (TOF+) m/z calcd for C36H36N8O8NaS
+:
763.2270, found: 763.2293; IR (neat) νmax 3280, 2922, 2104,
1663, 1579, 1294, 1260, 1103, 1047 cm−1; UV absorption λmax
489 nm, εmax 1.19 × 10
4 L mol−1 cm−1 (CHCl3); fluorescence
emission λmax 716 nm.
Pyrene-D-GlcN derivative (7). Carboxylic acid 3 (69 mg,
0.13 mmol), N-(6-aminohexyl)-4-(pyren-4-yl)butanamide hydro-
chloride 520 (66 mg, 0.16 mmol), TBTU (41 mg, 0.13 mmol)
and DIPEA (34 μL, 0.19 mmol) were dissolved in anhydrous
DMF (4 mL) under nitrogen and the reaction stirred for 44 h
whereupon it was shown to be complete by TLC analysis
(EtOAc/Hex, 4 : 1). The reaction solution was diluted with
diethyl ether (20 mL) and washed with water (7 × 20 mL). The
diethyl ether was removed in vacuo giving the crude product as
a pale yellow oil. This was purified by silica gel flash chromato-
graphy, eluting with EtOAc/hexane, 4 : 1 to yield 7 (45 mg,
0.05 mmol, 83%) as a colourless oil. Rf = 0.5 (EtOAc/Hex, 4 : 1);
[α]D +48.7 (c = 1.5, DCM);
1H NMR (400 MHz; CDCl3) δ 8.21 (d,
J = 9.3 Hz, 1H, ArH), 8.08 (d, J = 7.1 Hz, 2H, ArH), 8.01 (d, J =
8.2 Hz, 2H, ArH), 7.94 (s, 2H, ArH), 7.90 (t, J = 7.6 Hz, 1H, ArH),
7.77 (d, J = 7.8 Hz, 1H, ArH), 7.41–7.40 (m, 3H, ArH), 7.27–7.18
(m, 12H, ArH), 6.73 (t, J = 5.8 Hz, 1H, NH), 5.51 (d, J = 5.4 Hz,
1H, H1), 5.42–5.40 (brs, 1H, NH), 4.84 (d, J = 10.5 Hz, 1H,
CH2Ar), 4.61 (d, J = 10.5 Hz, 1H, CH2Ar), 4.46 (d, J = 11.9 Hz,
1H, CH2Ar), 4.36 (d, J = 11.9 Hz, 1H, CH2Ar), 4.22–4.19 (m, 1H,
H5), 4.14 (d, J = 15.3 Hz, 1H, CH2C(O)NH), 3.95 (d, J = 15.3 Hz,
1H, CH2C(O)NH), 3.83 (dd, J = 10.2, 5.4 Hz, 1H, CH2Pyr),
3.72–3.48 (m, 6H, H2, H3, H4, H6ab, CH2Pyr × 1), 3.30 (t, J =
7.2 Hz, 2H, CH2C(O)), 3.13–3.02 (m, 3H, CH2NH), 2.88–2.79
(m, 1H, CH2NH), 2.18–2.12 (m, 2H, CH2 alkyl), 1.31–1.10 (m,
8H, CH2 alkyl);
13C NMR (100 MHz, CDCl3) δ 172.7, 169.1,
137.3, 136.9, 135.9, 133.1, 132.1, 132.0, 131.4, 130.9, 129.9,
129.2, 128.7, 128.6, 128.4, 128.3, 128.0, 127.9, 127.8, 127.5,
127.4, 126.8, 125.9, 125.0, 124.9, 124.8, 123.4, 87.2, 81.0, 78.3,
75.9, 73.6, 71.5, 68.3, 64.2, 39.2, 38.4, 36.1, 32.8, 29.5, 27.5,
26.1; MS ES [M + Na]+ m/z 926.0; HRMS (TOF+) m/z calcd for
C54H58N5O6S: 904.4130, Found: 904.4081; IR (neat) νmax 3313,
3033, 2927, 2858, 2105, 1649, 1535, 1262, 1101, 1072, 1045,
1026 cm−1; UV absorption λmax1 279 nm, λmax2 329 nm, εmax1
3.42 × 104 L mol−1 cm−1, εmax2 2.69 × 10
4 L mol−1 cm−1
(CHCl3); fluorescence emission λmax1 327 nm, λmax2 207 nm.
Phenyl-2-azido-2-deoxy-3,6-di-O-benzyl-4-O-[(S)-2,3-bis-
(benzyloxy)propoxy]-1-thio-β-D-glucopyranoside (17)
To 1 (2.67 g, 5.60 mmol) was added dry DMF (30 mL) under N2
and the solution cooled to 0 °C. NaH (60% in mineral oil)
(248.0 mg, 6.2 mmol) was added in two portions over 30 min
while being kept under N2. 14
23 (2.49 g, 6.2 mmol) in dry DMF
(20 mL) was then added dropwise and the suspension allowed
to warm to RT and stirred for a further 3 h. TLC analysis (3/1,
hexane/EtOAc) showed the reaction to be complete and
quenching was eﬀected with aqueous NaHCO3 (1 mL). The
solution was partitioned between EtOAc and H2O. The layers
were separated and the organic phase washed with 1 M HCl,
H2O, brine, dried (MgSO4), filtered and evaporated. The crude
product was purified by flash column chromatography (EtOAc/
hexane gradient 1 : 9) yielding 17 (3.70 g, 5.1 mmol, 90%) as a
clear oil. Rf 0.71 (EtOAc/hexane 1 : 3); [α]D −19.1 (c = 3.0, DCM);
1H NMR (400 MHz; CDCl3) δ 7.53–7.50 (m, 2H, ArH), 7.27–7.15
(m, 23H, ArH), 4.76 (d, J = 10.5 Hz, 1H, CH2Ar), 4.73 (d, J = 10.6
Hz, 1H, CH2Ar), 4.55 (d, J = 12.0 Hz, 1H, CH2Ar), 4.51 (d, J =
12.0 Hz, 1H, CH2Ar), 4.45–4.38 (m, 4H, 2 × CH2Ar), 4.32 (d, J =
10.1 Hz, 1H, H1), 3.92–3.88 (m, 1H, H6A or H6B), 3.72–3.57 (m,
4H, H5, H6A or H6B, CH2CH[OBn]CH2OBn), 3.45–3.44 (m, 2H,
CH2CH[OBn]CH2OBn), 3.38–3.32 (m, 3H, H3, H4, CH2CH[OBn]-
CH2OBn), 3.22 (dd, J = 10.0, 9.0 Hz, 1H, H2);
13C NMR
(100 MHz; CDCl3) δ 138.5, 138.4, 138.2, 137.7, 133.7, 131.2,
129.1, 128.5, 128.4, 128.2, 128.0, 127.8, 127.7, 127.6, 127.5,
85.9, 84.9, 79.4, 78.2, 77.3, 75.8, 73.5, 73.4, 73.2, 72.4, 69.8,
68.8, 64.9; MS ES [M + NH4]
+ m/z 750.0; HRMS (ES-TOF+) m/z
calcd for C43H49N4O6S [M + NH4]
+ 749.3368, found 749.3365.
Phenyl-2-azido-2-deoxy-3-O-benzyl-4-O-[(S)-2,3-bis(benzyloxy)-
propoxy]-6-O-benzoyl-1-thio-β-D-glucopyranoside (18)
To 1612 (1.83 g, 3.72 mmol) was added dry THF (20 mL) under
N2 and the solution cooled to 0 °C. NaH (60% in mineral oil)
Organic & Biomolecular Chemistry Paper
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(164.0 mg, 4.10 mmol) was added in two portions over 30 min.
while being kept under N2. 14
23 (1.81 g, 4.46 mmol) in dry
THF (10 mL) was then added dropwise and the suspension
allowed to warm to RT and stirred for a further 2 h. TLC analy-
sis (3/1, hexane/EtOAc) showed the reaction to be virtually
complete (Note: allowing the reaction continue for longer
resulted in no further consumption of starting material and
the formation of another product; suggested to be transesteri-
fication) and quenching was eﬀected with glacial AcOH
(4.1 mmol) and solvents removed in vacuo. The solution was
partitioned between EtOAc and H2O. The layers were separated
and the organic phase washed with 1 M HCl, H2O, brine, dried
(MgSO4), filtered and evaporated. The crude product was puri-
fied by flash column chromatography (EtOAc/hexane gradient
1 : 9, 1 : 7) yielding 18 (1.26 g, 1.60 mmol, 69%) as a clear oil
along with recovered starting material 18 (979 mg). Rf 0.59
(EtOAc/hexane 1 : 3); [α]D −19.7 (c = 3.8, DCM); 1H NMR
(400 MHz; CDCl3) δ 7.97–7.94 (m, 2H, ArH), 7.56–7.52 (m, 1H,
ArH), 7.45–7.38 (m, 4H, ArH), 7.30–7.11 (m, 16H, ArH),
7.02–6.98 (m, 2H, ArH), 4.76 (d, J = 10.4 Hz, 1H, CH2Ar), 4.71
(d, J = 10.4 Hz, 1H, CH2Ar), 4.71 (dd, J = 12.0, 2.0 Hz, 1H, H6A
or H6B), 4.56 (d, J = 12.0 Hz, 1H, CH2Ar), 4.52 (d, J = 12.0 Hz,
1H, CH2Ar), 4.42 (d, J = 12.1 Hz, 1H, CH2Ar), 4.39 (d, J = 12.0
Hz, 1H, CH2Ar), 4.35–4.31 (m, 2H, H1, H6A or H6B), 3.99–3.98
(m, 1H, CH2CH[OBn]CH2OBn), 3.64–3.58 (m, 2H, CH2CH
[OBn]CH2OBn, CH2CH[OBn]CH2OBn), 3.54–3.50 (m, 1H, H5),
3.49–3.47 (m, 2H, CH2CH[OBn]CH2OBn), 3.40 (t, J = 9.6 Hz,
1H, H3), 3.34 (t, J = 9.6 Hz, 1H, H4), 3.20 (dd, J = 10.1, 9.6 Hz,
1H, H2);
13C NMR (100 MHz; CDCl3) δ 166.0, 138.4, 138.1,
137.5, 134.2, 133.4, 130.5, 130.0, 129.8, 129.0, 128.7, 128.6,
128.5, 128.4, 128.2, 127.8, 127.7, 85.6, 84.7, 78.4, 77.4, 77.2,
76.0, 73.5, 72.5, 69.5, 64.8, 63.1; MS ES [M + Na]+ m/z 768.0;
HRMS (TOF+) m/z calcd for C43H49N5O6S [M + NH4]
+ 763.3399,
found 763.3398.
Methyl (phenyl 4-O-(2-azido-3,6-di-O-benzyl-2-deoxy-4-O-[(S)-
2,3-bis(benzyloxy)propoxy]-α-D-glucopyranosyl)-2-O-benzoyl-3-
O-benzyl-1-thio-α-L-idopyranoside)-uronate (20)
To 17 (500 mg, 0.68 mmol) was added acetone (5.0 mL) and
the mixture cooled to 0 °C in an icebath. N-Bromosuccinimide
(242 mg, 1.36 mmol) was then added. After 3 h the reaction
was quenched by addition of aqueous NaHCO3 (2.0 mL) and
the solution stripped. The crude mixture was purified by flash
column chromatography using EtOAc/hexane (1 : 4, 1 : 3) as the
eluent to yield a mixture of hemi-acetals (333 mg, 0.52 mmol,
76%) as a white foam. The mixture of anomers was used
immediately. Rf 0.14 (EtOAc/hexane 1 : 3); MS ES: [M + Na]
+ m/z
663; HRMS (TOF-ES+): m/z calcd for C37H41N3O7Na [M + Na]
+:
662.2837, found 662.2836. See ESI† for copies of 1H and COSY
NMR spectra. To the mixture of hemi-acetals (1.8 g, 2.8 mmol)
was added dry DCM (40 mL), CCl3CN (1.40 mL, 14.0 mmol)
and sodium hydride 60% (11.0 mg, 0.3 mmol). The solution
was stirred for 1 h. The solvent was evaporated and the crude
residue purified by flash column chromatography using
EtOAc/hexane (1 : 4 + 1% NEt3) as eluent. This yielded the
desired imidate (1.70 g, 2.1 mmol, 95%) as a white foam and
as a 5/1 (α/β) mixture, as determined by 1H NMR. This com-
pound was used immediately. Rf 0.50 (EtOAc/hexane 1 : 3);
HRMS (FTMS-NSI+): m/z calcd for C39H45N5O7 [M + NH4]
+
800.2379, found 800.2377. See ESI† for copy of 1H NMR spec-
trum. To iduronic ester acceptor 1912 (833 mg, 1.78 mmol) and
the above imidate (1.70 g, 2.14 mmol) was twice added dry
toluene and the solvent evaporated. The residue was dried
under high vacuum for 2 h and, while kept under nitrogen,
dry DCM (25 mL) was added. The solution was cooled to
−30 °C using a 65 : 35 mixture of iPrOH/H2O and a dry ice bath
and TMSOTf (16 μL, 0.09 mmol) was then added. After 2 h the
reaction was quenched with two drops of NEt3, solvents were
removed in vacuo and flash column chromatography (EtOAc/
hexane, 1 : 5, 1 : 2) as the eluent yielded 20 (1.10 g, 0.99 mmol,
55%) as a white foam, along with recovered acceptor 19
(300 mg); Rf 0.31 (EtOAc/hexane 1 : 3); [α]D (c = 1.0, DCM)
+327.1; 1H NMR (400 MHz; CDCl3) δ 8.07–8.04 (m, 2H, ArH),
7.49–7.44 (m, 2H, ArH), 7.43–7.38 (m, 2H, ArH), 7.35–7.29 (m,
4H, ArH), 7.27–7.09 (m, 23H, ArH), 7.04–7.00 (m, 2H, ArH),
5.72 (s, 1H, H5), 5.35 (s, 1H, H4), 5.29 (d, J = 2.0 Hz, 1H, H1),
4.91 (d, J = 11.7 Hz, 1H, CH2Ph), 4.69 (d, J = 11.7 Hz, 1H,
CH2Ph), 4.61 (d, J = 3.6 Hz, 1H, H1′), 4.55–4.48 (m, 2H, CH2Ph),
4.43 (s, 2H, CH2Ph), 4.38–4.31 (m, 2H, CH2Ph), 4.18 (d, J = 10.6
Hz, 1H, CH2Ph), 4.12 (t, J = 2.8 Hz, 1H, H3), 3.97 (s, 1H, H2),
3.81 (dd, J = 9.7, 3.3 Hz, 1H, H6A′), 3.71–3.63 (m, 3H, CH2Ph,
CH2CH[OBn]CH2OBn), 3.61 (s, 3H, OCH3), 3.59–3.37 (m, 7H,
H5′, H6B′, H4′, H3′, CH2CH[OBn]CH2OBn, CH2CH[OBn]
CH2OBn,), 3.14 (dd, J = 10.0, 3.7 Hz, 1H, H2′);
13C NMR
(100 MHz; CDCl3) δ 169.3, 165.6, 138.6, 138.2, 137.9, 137.8,
137.1, 135.4, 133.4, 131.5, 130.0, 129.5, 129.1, 128.8, 128.5,
128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.6, 127.5,
100.4, 87.0, 80.0, 78.0, 77.6, 77.4, 74.6, 73.4, 73.3, 73.1, 72.8,
72.4, 72.2, 71.6, 70.1, 69.2, 68.4, 67.6, 63.6, 52.3; MS ES [M +
NH4]
+ m/z 1133.5; HRMS (FTMS-NSI+) m/z calcd for
C64H69N4O13S [M + NH4]
+ 1133.4576, found 1133.4578.
Methyl (phenyl 4-O-(2-azido-3-O-benzyl-6-O-benzoyl-2-deoxy-4-
O-[(S)-2,3-bis(benzyloxy)propoxy]-α-D-glucopyranosyl)-2-O-
benzoyl-3-O-benzyl-1-thio-α-L-idopyranoside)-uronate (21)
To 18 (1.26 g, 1.60 mmol) was added acetone (15.0 mL) and
the mixture cooled to 0 °C in an icebath. N-Bromosuccinimide
(569 mg, 3.20 mmol) was then added. After 2 h the reaction
was quenched by addition of aqueous NaHCO3 (2.0 mL) and
the solution stripped. The crude mixture was purified by flash
column chromatography using EtOAc/hexane (1 : 4) as the
eluent to yield the mixture of hemi-acetals (963 mg,
1.40 mmol, 87%) as a pale yellow oil. This mixture of anomers
was used immediately. Rf 0.24 (EtOAc/hexane 1 : 3); MS ES: [M
+ Na]+ m/z 676; HRMS (TOF-ES+): m/z calcd for C37H39N3O8Na
[M + Na]+: 676.2630, found 676.2634. See ESI† for copies of 1H
and COSY NMR spectra. To this mixture of hemi-acetals
(963 mg, 1.40 mmol) was added dry DCM (10 mL), CCl3CN
(421 μL, 4.20 mmol) and sodium hydride 60% (6.0 mg,
0.14 mmol). The solution was stirred for 2 h. The solvent was
evaporated and the crude residue purified by flash column
chromatography using EtOAc/hexane (1 : 5 + 1% NEt3) as
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eluent. This yielded the desired imidate (918 mg, 1.09 mmol,
77%) as a pale yellow foam and a 95/5 α/β mixture, as deter-
mined by 1H NMR. This compound was used immediately.
Rf 0.57 (EtOAc/hexane 1 : 3). See ESI† for copy of
1H NMR spec-
trum. To iduronic ester acceptor 1912 (441 mg, 0.89 mmol) and
the above imidate (900 mg, 1.07 mmol) was twice added dry
toluene and the solvent evaporated. The residue was dried
under high vacuum for 2 h and, while kept under nitrogen,
dry DCM (15 mL) was added. The solution was cooled to
−30 °C using a 65 : 35 mixture of iPrOH/H2O and a dry ice bath
and TMSOTf (8 μL, 0.04 mmol) was then added. After 0.5 h the
reaction was quenched with two drops of NEt3, solvents were
removed in vacuo and flash column chromatography (EtOAc/
hexane, 1 : 7, 1 : 6, 1 : 5, 1 : 3) as the eluent yielded 21 (472 mg,
0.42 mmol, 47%) as a white foam, along with recovered accep-
tor 19 (123 mg). Rf 0.44 (EtOAc/hexane 1 : 3); [α]D (c = 0.75,
DCM) +287.1; 1H NMR (400 MHz; CDCl3) δ 8.18 (dd, J = 8.4,
1.3 Hz, 2H, ArH), 8.02 (dd, J = 8.4, 1.3 Hz, 2H, ArH), 7.60–7.58
(m, 3H, ArH), 7.52–7.50 (m, 2H, ArH), 7.46–7.40 (m, 6H, ArH),
7.37–7.24 (m, 16H, ArH), 7.22–7.20 (m, 2H, ArH), 7.15 (td, J =
3.7, 1.7 Hz, 2H, ArH), 5.84 (brs, 1H, H1), 5.46 (brs, 1H, H2),
5.43 (d, J = 2.0 Hz, 1H, H5), 5.02 (d, J = 11.7 Hz, 1H, CH2Ph),
4.81–4.77 (m, 2H, CH2Ph, H6A), 4.72 (d, J = 3.6 Hz, 1H, H1′),
4.66–4.59 (m, 2H, CH2Ph), 4.57–4.49 (m, 2H, CH2Ph), 4.43 (dd,
J = 12.4, 2.7 Hz, 1H, H6B), 4.25–4.22 (m, 2H, H3, CH2Ph), 4.11
(brs, 1H, H4), 4.06–4.00 (m, 2H, H5′, CH2CH[OBn]CH2OBn),
3.84–3.81 (m, 4H, OCH3, CH2Ph), 3.73–3.67 (m, 2H, CH2CH
[OBn]CH2OBn), 3.62–3.60 (m, 2H, CH2CH[OBn]CH2OBn),
3.55–3.44 (m, 2H, H3′, H4′), 3.23 (dd, J = 9.9, 3.6 Hz, 1H, H2′);
13C NMR (100 MHz; CDCl3) δ 167.0, 163.7, 163.3, 136.2, 135.9,
135.4, 134.9, 133.2, 131.2, 130.9, 129.2, 127.8, 127.7, 127.4,
126.9, 126.8, 126.6, 126.3, 126.2, 126.1, 126.0, 125.9, 125.7,
125.5, 125.4, 123.1, 97.9, 84.8, 77.7, 76.5, 72.5, 71.2, 71.1, 70.5,
70.2, 69.8, 68.1, 67.5, 67.1, 66.1, 61.6, 50.3; MS ES [M + Na]+
m/z 1153; HRMS (FTMS-NSI+) m/z calcd for C64H67N4O14S1 [M
+ NH4]
+ 1147.4369, found 1147.4357.
Dodecasaccharide (24). Decasaccharide acceptor 225
(391.0 mg, 0.10 mmol) and disaccharide donor 20 (138.0 mg,
0.12 mmol) were combined in dry toluene (10 mL). Solvent
was removed in vacuo and the residue dried under high
vacuum for 1 h. The resulting foam was then dissolved in dry
DCM (5.0 mL) and cooled to 0 °C. 4 Å molecular sieves
(100 mg) were added followed by NIS (29.0 mg, 0.13 mmol)
and AgOTf (2.6 mg, 10.0 μmol. The resultant suspension was
stirred at this temperature for 0.5 h whereupon a deep red
colour persisted. The reaction was quenched with NaHCO3
(25 mg) and Na2S2O3 (25 mg) in H2O (1.0 mL) and the mixture
filtered through a Celite™ plug, washing with DCM. The layers
were separated and the organics dried (MgSO4) and solvent
removed in vacuo to reveal crude 24 as a yellow gum. The
material was then purified by silica gel flash chromatography
eluting with toluene/acetone, 20/1 to separate the product and
unreacted decasaccharide acceptor 22 (131 mg recovered). The
product 24 (367 mg, 76.0 μmol, 77%) was isolated as a white
foam. Rf 0.38 (toluene/acetone 10 : 1); [α]D (c = 1.1, DCM) +42.9;
1H NMR (400 MHz; CDCl3) δ 8.13–8.10 (m, 3H, ArH), 8.01–7.92
(m, 11H, ArH), 7.54–7.07 (m, 116H, ArH), 5.57–5.56 (m, 5H,
H1IdoA), 5.21–5.18 (m, 5H, H2IdoA), 5.10 (s, 1H, H1IdoA), 5.06 (s,
1H, H2IdoA), 4.97–4.90 (m, 6H, H1GlcN), 4.82–4.38 (m, 43H),
4.24–3.25 (m, 78H, incl. C(O)OCH3 × 6, OCH3);
13C NMR
(100 MHz; CDCl3) δ 169.6, 169.4, 169.3, 167.7, 165.6, 165.2,
165.1, 138.6, 138.1, 138.0, 137.9, 137.8, 137.7, 137.5, 137.4,
133.6, 133.5, 132.3, 131.0, 130.0, 129.9, 129.8, 129.6, 129.4,
129.3, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.4,
128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5,
127.4, 127.3, 125.4, 100.3, 99.5, 99.3, 99.2, 98.2, 98.1, 98.0,
79.6, 78.3, 78.2, 78.1, 77.5, 77.4, 77.2, 76.9, 76.0, 75.6, 75.5,
75.4, 74.9, 74.4, 74.2, 74.0, 73.7, 73.6, 73.5, 73.4, 73.2, 72.5,
72.4, 71.6, 71.4, 70.7, 70.1, 68.0, 67.7, 67.4, 67.3, 67.2, 63.4,
63.3, 63.2, 63.1, 63.0, 61.7, 56.3, 52.1, 51.9, 51.8, 51.7, 51.6;
(MS MALDI) m/z calcd for C264H268N18O69Na [M + Na]
+ 4819.8,
found 4819.8.
Decasaccharide (25). Octasaccharide acceptor 234
(161.0 mg, 52.0 μmol) and disaccharide donor 21 (71 mg,
62.0 μmol) were combined in dry toluene (10 mL). Solvent was
removed in vacuo and the residue dried under high vacuum for
1 h. The resulting foam was then dissolved in dry DCM
(5.0 mL) and cooled to 0 °C. 4 Å molecular sieves (100 mg)
were added followed by NIS (15.2 mg, 68.0 μmol) and AgOTf
(1.3 mg, 5.2 μmol. The resultant suspension was stirred at this
temperature for 0.5 h whereupon a deep red colour persisted.
The reaction was quenched with NaHCO3 (25 mg) and Na2S2O3
(25 mg) in H2O (1.0 mL) and the mixture filtered through a
Celite™ plug, washing with DCM. The layers were separated
and the organics dried (MgSO4) and solvent removed in vacuo
to reveal crude 25 as a yellow gum. The material was then puri-
fied by silica gel flash chromatography eluting with toluene/
acetone, 30/, 25/1, 20/1 to separate the product and unreacted
octasaccharide acceptor 23 (52 mg recovered). The product was
then purified again by silica gel flash chromatography eluting
with hexane/EtOAc, 2/1, 1/1 to give 25 (82 mg, 20.0 μmol, 57%)
as a white foam. Rf 0.29 (Ether/DCM 5 : 95); [α]D (c = 0.5, DCM)
+63.4; 1H NMR (400 MHz; CDCl3) δ 8.01–7.95 (m, 24H, ArH),
7.17–7.11 (m, 86H, ArH), 5.50–5.48 (m, 4H, H1IdoA), 5.13–5.08
(m, 4H, H2IdoA), 4.99 (brs, 1H, H1IdoA), 4.97 (brs, 1H, H2IdoA),
4.83–4.16 (m, 43H, CH2Ar × 23, H5IdoA, H1GlcN, H6ABGlcN),
4.06–4.70 (m, 21H, CH2Ar × 4, H3IdoA, H4IdoA, H5GlcN, H4GlcN × 4,
CH2CH[OBn]CH2OBn), 3.65–3.56 (m, 2H, CH2CH[OBn]
CH2OBn), 3.53 (s, 3H, OCH3), 3.47–3.42 (m, 14H, H3GlcN,
H4GlcN × 1, CH2CH[OBn]CH2OBn C(O)OCH3 × 2), 3.25–3.04 (m,
14H, H2GlcN, C(O)OCH3 × 3);
13C NMR (100 MHz; CDCl3)
δ 169.6, 169.3, 169.2, 166.0, 165.9, 165.6, 165.2, 165.1, 138.3,
138.0, 137.7, 137.5, 137.4, 137.3, 137.2, 133.7, 133.5, 133.1,
133.0, 132.5, 129.9, 129.6, 128.8, 128.7, 128.5, 128.4, 128.3,
128.2128.1, 128.0, 127.8, 127.6, 100.3, 99.1, 98.7, 98.4, 98.3,
98.3, 98.2, 98.1, 98.1, 98.0 anomeric carbons], 79.7, 78.6, 78.4,
78.3, 78.2, 77.8, 77.7, 77.6, 77.5, 77.3, 77.2, 77.0, 76.9, 76.7,
76.3, 75.9, 75.8, 75.7, 75.6, 75.4, 75.1, 75.0, 74.6, 74.5, 74.4,
74.3, 74.2, 73.9, 73.5, 72.4, 72.3, 71.7, 71.2, 70.2, 70.0, 69.9,
69.8, 69.6, 68.0, 67.1, 63.4 63.3, 63.2, 63.0, 62.3, 61.9, 61.8,
56.2, 52.3, 51.9, 51.7, 51.6, 51.6; (FTMS NSI+) m/z calcd for
C223H225N17O63 [M+2NH4]
2+ 2074.2457, found 2074.2422;
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General method for saponification of oligosaccharides 24 and 25
Decasaccharide 25 (71.4 mg, 17.4 μmol) was dissolved in THF
(1 mL) and MeOH (0.5 mL). The solution was cooled to 0 °C
and LiOH (22.0 mg, 522.5 μmol) in H2O (0.5 mL) added drop-
wise, whereupon the solution turned a faint yellow colour. Stir-
ring was continued for 5 h at this temperature, at room
temperature overnight and quenched with 1 M HCl (520 μL).
Solvents were removed in vacuo and the crude white solid puri-
fied by silica gel flash chromatography, eluting with DCM/
MeOH, 95/5, 90/10 to give the decasaccharide acid (31.0 mg,
10.0 μmol, 60%) as a white solid. Rf 0.41 (MeOH/DCM 1 : 9);
1H NMR (400 MHz; Acetic acid, d4) δ 7.36–6.97 (m, 60H, ArH),
5.22–5.15 (m, 4H, H1IdoA), 5.03 (s, 3H, H1GlcN), 4.99–4.98 (m,
2H, H1GlcN), 4.87 (s, 1H, H1IdoA), 4.81–4.80 (m, 4H), 4.73 (s,
1H), 4.69–4.60 (m, 8H), 4.56–4.51 (m, 8H), 4.47–4.39 (m, 4H),
4.36 (d, J = 2.9 Hz, 2H), 4.33–4.25 (m, 4H), 4.13 (s, 1H),
4.04–4.01 (m, 5H), 3.96–3.77 (m, 21H), 3.69–3.40 (m, 30H),
3.33 (brs, 4H, includes OCH3); HRMS (FTMS NSI
−) m/z calcd
for C148H165N15O53 [M − 2H]2− 1500.0344, found 1500.0334.
Reaction of compound 24 (350 mg, 73.0 μmol) following
the above procedure yielded the product dodecasaccharide
acid (235 mg, 57.0 μmol, 79%). Rf 0.49 (MeOH/DCM 1 : 9); 1H
NMR (400 MHz; MeOD) δ 7.56–7.16 (m, 100H, ArH), 5.32–5.30
(brs, 6H, H1IdoA), 5.14–5.12 (brs, 6H, H1GlcN), 4.78–3.44 (m,
60H, H2GlcN, H3GlcN, H4GlcN, H5GlcN, H6abGlcN, H2IdoA, H3IdoA,
H4IdoA, H5IdoA); HRMS (FTMS NSI
−) m/z calcd for
C216H229N18O63 [M − 3H]3− 1360.8428, found 1360.8405.
General method for O-sulfation and hydrogenation of
oligosaccharides
The above decasaccharide acid (31.0 mg, 10.0 μmol) was dis-
solved in dry pyridine (1 mL) under N2 at RT. SO3·Py complex
(66 mg, 414 μmol) was added and the suspension stirred 50 °C
for 5 h then at RT overnight. A white precipitate formed from
the pale yellow solution after 2 h. TLC analysis (EtOAc/Pyr/
H2O/AcOH, 6/5/3/1) showed no starting material remained and
one product spot had formed at lower Rf. The reaction was
quenched by addition of NaHCO3 (102 mg) in H2O (0.5 mL)
and the solvents removed in vacuo (co-evaporationg with
toluene). The crude white paste was then purified by silica gel
flash chromatography, eluting with DCM/MeOH, 9/1, 4/1. The
residue obtained was dissolved in MeOH/DCM (2 mL, v/v),
stirred with Amberlite IR120+-Na+ resin for 12 h, filtered and
solvent removed in vacuo to give target O-sulfated species
(24.0 mg, 5.8 μmol, 56%) as a white solid which was used
immediately in the next step. Rf 0.37 (MeOH/DCM/NH4OH
6 : 14 : 2). This material (11.1 mg, 2.7 μmol) was dissolved in
MeOH (0.5 mL) and THF (0.5 mL) at RT. NaHCO3 (5 mg,
54 μmol) in H2O (0.5 mL) was added along with Pd(OH)2/C
(10 mg) and the system purged with H2. Stirring was continued
at 50 °C for 4 d. The suspension was then filtered through
Celite® and solvents removed in vacuo. The residue was dis-
solved in water and desalted by passage through a Sephadex
G-20 resin using water as eluent to reveal the free sugar
(4.6 mg, 1.6 μmol, 59%) as a clear glass. 1H NMR (400 MHz;
D2O) δ 5.07.5.05 (m, 3H, H1IdoA), 5.98–4.92 (m, 4H, H1GlcN),
4.88 (s, 1H, H1IdoA), 4.81–4.78 (m, 4H, H5IdoA), 4.36 (s, 1H,
H5IdoA), 4.22–4.05 (m, 20H, H2IdoA, H3IdoA, H6GlcN), 3.99–3.70
(m, 13H, H4IdoA, H5GlcN, 3H from NRE tether), 3.65–3.42 (m,
11H, H3GlcN, H4GlcN, 2H from NRE tether), 3.28 (s, 3H, OCH3),
3.27–3.19 (m, H4GlcN), 2.69–2.59 (m, 5H, H2GlcN); HRMS (FTMS
NSI−) m/z calcd for C64H99N5O83S10 [M − 6H]6− 430.8487,
found 430.8491, calcd for C64H100N5O83S10 [M − 5H]5−
517.2198, found 517.2206.
Reaction of the above dodecasaccharide acid (170.0 mg,
42.0 μmol) following the above O-sulfation procedure yielded
the target O-sulfated species (120.0 mg, 25.0 μmol, 60%) which
was used immediately in the next step. Rf 0.69 (MeOH/DCM,
1 : 5); FTMS (NSI−) m/z calcd for C216H226N18O81S6 [M − 6H]6−
760.8746, found 760.8747. Reaction of this compound
(65.0 mg, 13.5 μmol) following the above hydrogenation pro-
cedure yielded the free sugar (30.0 mg, 13.4 μmol, quant.). 1H
NMR (400 MHz; D2O) δ 5.05–5.03 (brs, 5H, H1IdoA), 4.91–4.88
(m, 7H, H1GlcN × 6, H1IdoA), 4.78 (brs, 5H, H5IdoA), 4.36 (s, 1H,
H5IdoA), 4.20 (brs, 5H, H2IdoA), 4.11–4.02 (m, 7H, H3IdoA × 6,
H2IdoA), 3.95–3.87 (m, 6H, H4IdoA), 3.76–3.68 (m, 19H, H5GlcN
H6ABGlcN, 1H NRE tether), 3.56–3.45 (15H, H3GlcN H4GlcN × 5,
4H NRE tether), 3.29 (s, 3H, OMe), 3.23–3.17 (m, 1H, H4GlcN),
2.59–2.55 (m, 6H, H2GlcN); HRMS (FTMS-NSI
−) m/z calcd for
C76H118N6O81S6 [M − 6H]6− 433.7276, found 433.7262, calcd
for C76H119N6O81S6 [M − 5H]5− 520.6746, found 520.6732.
General method for N-sulfation of oligosaccharides
The decasaccharide free sugar (4.0 mg, 1.4 μmol) was dissolved
in H2O (0.5 mL) at RT. NaHCO3 (10.1 mg, 120 μmol) and
SO3·pyr complex (9.5 mg, 60.0 μmol) were then added and the
suspension stirred at room temperature. Further additions of
both reagents were made at 1 h, 3 h, 8 h, 20 h and 24 h. After
28 h solvent was removed in vacuo to reveal a crude white solid
which was purified by passage through a Sephadex G-20 resin
using water as eluent. The target material (4.6 mg, 1.4 μmol,
90%) was isolated as a clear glass. This material was used
immediately in the periodate cleavage step.
Reaction of the dodecasaccharide free sugar (30.0 mg,
10.8 μmol) following the above procedure yielded the product
(35.0 mg, 9.1 μmol, 92%). 1H NMR (400 MHz; D2O) δ 5.21–5.14
(m, 11H, H1IdoA, H1GlcN), 4.90 (brs, 1H, H1IdoA), 4.75–4.73 (m,
5H, H5IdoA), 4.32 (s, 1H, H5IdoA), 4.21–4.19 (m, 6H, H2IdoA),
4.11–4.09 (m, 6H, H3IdoA), 3.95–3.45 (m, 41H, H4IdoA, H5GlcN
H6ABGlcN, H3GlcN H4GlcN, NRE tether, 5H), 3.29 (s, 3H, OMe),
3.13–3.09 (m, 6H, H2GlcN); HRMS (FTMS-NSI
−) m/z calcd for
C76H118N6O99S12 [M − 6H]6− 513.6844, found 513.6840,
C76H117N6O99S12 [M − 7H]6− 440.1570, found 440.1567.
General method for periodate cleavage of oligosaccharide NRE
tether 26 and 27
The N-sulfated decasaccharide (4.6 mg, 1.4 μmol) was dis-
solved in H2O (200 μL) at room temperature. NaIO4 (0.4 mg,
1.5 μmol) was added and the solution shaken in a 2.0 mL
Eppendorf tube for 24 h. The reaction solution was diluted up
to 1.0 mL with H2O and passed through a Sephadex G-20 resin
Paper Organic & Biomolecular Chemistry
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using water as eluent. The target material 27 (4.3 mg,
1.3 μmol, 95%) was isolated as a white glass after freeze-
drying. 1H NMR (600 MHz; D2O) δ 5.27–2.24 (m, 5H, H1GlcN),
5.08 (brs, 4H, H1IdoA), 4.88 (s, 1H, H1IdoA), 4.78 (brs, 4H,
H5IdoA), 4.39 (brs, 1H, H5IdoA), 4.21–4.00 (m, 23H), 3.89–3.77
(m, 11H), 3.67–3.65 (m, 6H), 3.26 (s, 3H, OCH3), 3.24–3.21 (m,
5H, H2GlcN); HRMS (FTMS NSI
−) m/z calcd for C63H95N5O82S10
[M − 6H]6− 425.5110, found 425.5115.
Reaction of the N-sulfated dodecasaccharide (30.0 mg,
8.6 μmol) following the above procedure yielded the product
26 (26.3 mg, 7.6 μmol, 88%). 1H NMR (800 MHz; D2O)
δ showed a complex mixture of cyclic acetal forms. See ESI† for
copies of 800 MHz 1D and 2D NMR spectra; HRMS
(FTMS-NSI−) m/z calcd for C75H112N6O98S12 [M − 8H]8−
381.0066, found 381.0082.
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